AIM:To observe the efficacy and safety of intravitreal Ranibizumab injection in patiens with choroidal neovascularization(CNV)secondary to pathologic myopia.

METHODS:In this retrospective and comparative study,24 patients(25 eyes)with CNV secondary to pathologic myopia were enrolled. All patients were assessed by examinations of ETDRS visual acuity chart, preplaced-mirror ophthalmoscopy, fundus fluorescein angiography(FFA), indocyanine green angiography(ICGA)and optical coherence tomography(OCT). Patiens received intravitreally injected ranibizumab 0.5mg(0.05mL). Treatments were repeated if the follow-up indicated that it was necessary. The follow-up periods were 4～10mo. Best corrected visual acuity(BCVA), central macular thickness(CMT)and leakage of CNV before and after the treatment were compared.

RESULTS:No local or systemic complications occurred in any patients during the treatment or follow-up. The average time of injection was 1.52. The mean BCVA was 23.93±12.46 letters before the therapy. In the last follow-up, the mean BCVA was 40.63±7.25 letters, improved by 14.27±9.36 letters and the difference was statically significant(t=5.74, P<0.05). The mean CMT was 363.47±119.62μm before treatments and 190.31±37.02μm after treatments which was 72.82±60.57 μm less than the pre-treatment values and the difference was statically significant(t=3.96, P<0.05).

CONCLUSION:Intravitreal ranibizumab injection for CNV secondary to pathologic myopia is safe and effective, and this treatment can improve visual acuity, reduce retina edema and leakage of CNV.